BioNTech SE : Q3 exceeds expectations. 2024 guidance adjusted
>Top line positively impacted by advantageous phasing of COVID 19 vaccine approvals - BioNtech reported Q3 figures that beat expectations at the level of sales (+183%) and EPS (€ 0.8 vs consensus -€ 1.5). Sales amounted to € 1,244m in Q3 (39% y-o-y), bringing sales in the first 9 months to € 1,560m (-33% y-o-y). This good performance in Q3 mainly reflected the approvals received earlier for its new COVID 19 vaccines vs 2023. R&D costs rose 11% to € 550m, 15% below th...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.